Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Orforglipron

RESTRAIN-SUI

Eli Lilly · Phase 3 · Recruiting · Enrollment 1000

NCT07202884

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Orforglipron (GZS1)n/rn/rn/rn/r
Placebo (GZS1)n/rn/rn/rn/r
Orforglipron (GZS2)n/rn/rn/rn/r
Placebo (GZS2)n/rn/rn/rn/r

Not shown

  • Orforglipron (GZS1): endpoint not reported
  • Placebo (GZS1): endpoint not reported
  • Orforglipron (GZS2): endpoint not reported
  • Placebo (GZS2): endpoint not reported